Mutations in BCR-ABL kinase domain are associated with resistance to tyrosine kinase inhibitors in some patients with chronic myeloid leukemia. Therefore, mutation detection becomes essential in such patients. We aimed to apply high-resolution melt curve analysis (HRM) for a rapid screening prior to sequencing to select only mutation positive samples. One hundred and one samples with different mutations and mutational ratios were used for HRM testing. HRM results of 100/101 samples were concordant with sequencing data. We found HRM as a suitable and sensitive method for initial rapid screening of BCR-ABL KD mutations to sequence only positive samples.

Institute of Hematology and Blood Transfusion Prague Czech Republic

References provided by Crossref.org

Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood

Expression patterns of microRNAs associated with CML phases and their disease related targets

CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis